Anti-oligomeric Aβ Single-chain Variable Domain Antibody Blocks Aβ-induced Toxicity Against Human Neuroblastoma Cells

Journal of Molecular Biology

Volumn 384, Issue 4, 2008, Pages 917-928

  Zameer, Andleeb ^a   Kasturirangan, Srinath ^a   Emadi, Sharareh ^a   Nimmagadda, Sridevi V ^a   Sierks, Michael R ^a  

^a Arizona State University   (United States)

Author keywords

Alzheimer's disease; A ; oligomers; phage display; ScFv

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; OLIGOMER; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; AMYLOID BETA PROTEIN; ANTIBODY; PEPTIDE LIBRARY;

ALZHEIMER DISEASE; ARTICLE; ATOMIC FORCE MICROSCOPY; BACTERIOPHAGE; BIOPANNING; BRAIN TISSUE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DOMAIN; TOXICITY; BRAIN; DRUG ANTAGONISM; IMMUNOLOGY; ISOLATION AND PURIFICATION; PATHOLOGY; TUMOR CELL LINE;

AMYLOID BETA-PROTEIN; ANTIBODIES; BRAIN; CELL LINE, TUMOR; HUMANS; MICROSCOPY, ATOMIC FORCE; PEPTIDE LIBRARY;

EID: 56249092747     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2008.09.068     Document Type: Article

References (64)

1. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 6 (1991) 487-498
2. Busciglio J., Lorenzo A., Yeh J., and Yankner B.A. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14 (1995) 879-888
3. Hardy J., Duff K., Hardy K.G., Perez-Tur J., and Hutton M. Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nature Neurosci. 1 (1998) 355-358
4. Hardy J.A., and Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 256 (1992) 184-185
5. Lorenzo A., and Yankner B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl Acad. Sci. USA 91 (1994) 12243-12247
6. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., and Cotman C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13 (1993) 1676-1687
7. Dickson D.W., Crystal H.A., Bevona C., Honer W., Vincent I., and Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging 16 (1995) 285-304
8. Katzman R. Alzheimer's disease. N. Engl. J. Med. 314 (1986) 964-973
9. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30 (1991) 572-580
10. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nature Neurosci. 5 (2002) 452-457
11. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22 (2002) 6331-6335
12. Oda T., Pasinetti G.M., Osterburg H.H., Anderson C., Johnson S.A., and Finch C.E. Purification and characterization of brain clusterin. Biochem. Biophys. Res. Commun. 204 (1994) 1131-1136
13. Oda T., Wals P., Osterburg H.H., Johnson S.A., Pasinetti G.M., Morgan T.E., et al. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp. Neurol. 136 (1995) 22-31
14. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95 (1998) 6448-6453
15. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 (1999) 860-866
16. Enya M., Morishima-Kawashima M., Yoshimura M., Shinkai Y., Kusui K., Khan K., et al. Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. Am. J. Pathol. 154 (1999) 271-279
17. Funato H., Enya M., Yoshimura M., Morishima-Kawashima M., and Ihara Y. Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Am. J. Pathol. 155 (1999) 23-28
18. Roher A.E., Chaney M.O., Kuo Y.M., Webster S.D., Stine W.B., Haverkamp L.J., et al. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 271 (1996) 20631-20635
19. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
20. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., and Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nature Neurosci. 8 (2005) 79-84
21. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., and Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27 (2007) 2866-2875
22. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
23. Dineley K.T., Xia X., Bui D., Sweatt J.D., and Zheng H. Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J. Biol. Chem. 277 (2002) 22768-22780
24. Jacobsen J.S., Wu C.C., Redwine J.M., Comery T.A., Arias R., Bowlby M., et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 103 (2006) 5161-5166
25. Walsh D.M., and Selkoe D.J. Abeta Oligomers - a decade of discovery. J. Neurochem. 101 (2007) 1172-1184
26. Maloney M.T., Minamide L.S., Kinley A.W., Boyle J.A., and Bamburg J.R. Beta-secretase-cleaved amyloid precursor protein accumulates at actin inclusions induced in neurons by stress or amyloid beta: a feedforward mechanism for Alzheimer's disease. J. Neurosci. 25 (2005) 11313-11321
27. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nature Neurosci. 8 (2005) 1051-1058
28. Kelly B.L., and Ferreira A. beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J. Biol. Chem. 281 (2006) 28079-28089
29. Tamagno E., Bardini P., Guglielmotto M., Danni O., and Tabaton M. The various aggregation states of beta-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. Free Radic. Biol. Med. 41 (2006) 202-212
30. Zhao L., Ma Q.L., Calon F., Harris-White M.E., Yang F., Lim G.P., et al. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nature Neurosci. 9 (2006) 234-242
31. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nature Rev. Neurosci. 3 (2002) 824-828
32. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
33. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
34. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
35. Birmingham K., and Frantz S. Set back to Alzheimer vaccine studies. Nature Med. 8 (2002) 199-200
36. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003) 46-54
37. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003) 547-554
38. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., et al. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl Acad. Sci. USA 100 (2003) 2023-2028
39. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6 (2000) 916-919
40. Bacskai B.J., Kajdasz S.T., McLellan M.E., Games D., Seubert P., Schenk D., and Hyman B.T. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci. 22 (2002) 7873-7878
41. Liu R., Yuan B., Emadi S., Zameer A., Schulz P., McAllister C., et al. Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry 43 (2004) 6959-6967
42. Zameer A., Schulz P., Wang M.S., and Sierks M.R. Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42. Biochemistry 45 (2006) 11532-11539
43. Barkhordarian H., Emadi S., Schulz P., and Sierks M.R. Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Eng. Des. Sel. 19 (2006) 497-502
44. Emadi S., Barkhordarian H., Wang M.S., Schulz P., and Sierks M.R. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J. Mol. Biol. 368 (2007) 1132-1144
45. Lambert M.P., Velasco P.T., Chang L., Viola K.L., Fernandez S., Lacor P.N., et al. Monoclonal antibodies that target pathological assemblies of Abeta. J. Neurochem. 100 (2007) 23-35
46. Kayed R., and Glabe C.G. Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol. 413 (2006) 326-344
47. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
48. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
49. Butler A.E., Janson J., Soeller W.C., and Butler P.C. Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52 (2003) 2304-2314
50. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Harper J.D., Williamson R.E., and Lansbury Jr. P.T. Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann. NY Acad. Sci. 920 (2000) 42-45
51. Reixach N., Deechongkit S., Jiang X., Kelly J.W., and Buxbaum J.N. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc. Natl Acad. Sci. USA 101 (2004) 2817-2822
52. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl Acad. Sci. USA 100 (2003) 10417-10422
53. Chang L., Bakhos L., Wang Z., Venton D.L., and Klein W.L. Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. J. Mol. Neurosci. 20 (2003) 305-313
54. Georganopoulou D.G., Chang L., Nam J.M., Thaxton C.S., Mufson E.J., Klein W.L., and Mirkin C.A. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl Acad. Sci. USA 102 (2005) 2273-2276
55. Lemere C.A., Spooner E.T., LaFrancois J., Malester B., Mori C., Leverone J.F., et al. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol. Dis. 14 (2003) 10-18
56. Das P., Howard V., Loosbrock N., Dickson D., Murphy M.P., and Golde T.E. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J. Neurosci. 23 (2003) 8532-8538
57. Chauhan N.B., and Siegel G.J. Efficacy of anti-Abeta antibody isotypes used for intracerebroventricular immunization in TgCRND8. Neurosci. Lett. 375 (2005) 143-147
58. Agadjanyan M.G., Ghochikyan A., Petrushina I., Vasilevko V., Movsesyan N., Mkrtichyan M., et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 174 (2005) 1580-1586
59. Gelinas D.S., DaSilva K., Fenili D., St George-Hyslop P., and McLaurin J. Immunotherapy for Alzheimer's disease. Proc. Natl Acad. Sci. USA 101 Suppl 2 (2004) 14657-14662
60. Schenk D., Hagen M., and Seubert P. Current progress in beta-amyloid immunotherapy. Curr. Opin. Immunol. 16 (2004) 599-606
61. Klein W.L. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41 (2002) 345-352
62. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., Viola K.L., et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 24 (2004) 10191-10200
63. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., and Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222 (1991) 581-597
64. LeVine III H. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2 (1993) 404-410